Impact of COVID-19 on Cardiovascular Disease.
Ivan VoskoAndreas ZirlikHeiko BuggerPublished in: Viruses (2023)
Coronavirus disease 2019 (COVID-19) is a viral infection with the novel severe acute respiratory distress syndrome corona virus 2 (SARS-CoV-2). Until now, more than 670 million people have suffered from COVID-19 worldwide, and roughly 7 million death cases were attributed to COVID-19. Recent evidence suggests an interplay between COVID-19 and cardiovascular disease (CVD). COVID-19 may serve as a yet underappreciated CVD risk modifier, including risk factors such as diabetes mellitus or arterial hypertension. In addition, recent data suggest that previous COVID-19 may increase the risk for many entities of CVD to an extent similarly observed for traditional cardiovascular (CV) risk factors. Furthermore, increased CVD incidence and worse clinical outcomes in individuals with preexisting CVD have been observed for myocarditis, acute coronary syndrome, heart failure (HF), thromboembolic complications, and arrhythmias. Direct and indirect mechanisms have been proposed by which COVID-19 may impact CVD and CV risk, including viral entry into CV tissue or by the induction of a massive systemic inflammatory response. In the current review, we provide an overview of the literature reporting an interaction between COVID-19 and CVD, review potential mechanisms underlying this interaction, and discuss preventive and treatment strategies and their interference with CVD that were evaluated since the onset of the COVID-19 pandemic.
Keyphrases
- cardiovascular risk factors
- coronavirus disease
- sars cov
- cardiovascular disease
- metabolic syndrome
- risk factors
- respiratory syndrome coronavirus
- heart failure
- acute respiratory distress syndrome
- acute coronary syndrome
- inflammatory response
- type diabetes
- systematic review
- emergency department
- coronary artery disease
- left ventricular
- toll like receptor
- adipose tissue
- intensive care unit
- drug induced
- big data
- mechanical ventilation
- adverse drug
- breast cancer risk